Publisher： Science Publishers
ISSN： 2049-9450
Source： Molecular and Clinical Oncology, Vol.3, Iss.4, 2015-01, pp. : 889-891
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Therapy with crizotinib achieves prolonged progression-free and overall survival in non-small-cell lung cancer (NSCLC) patients with echinoderm microtubuleassociated proteinlike 4 (EML4)anaplastic lymphoma kinase (ALK). It was demonstrated that ALKpositive NSCLCs exhibit a high response rate to the ALK inhibitor, crizotinib. However, a proportion of the patients discontinue crizotinib treatment due to adverse events. This is the case report of a NSCLC patient with EML4ALK rearrangement, who, following crizotinib discontinuation for one year due to adverse events, exhibited a marked response to alectinib. Even if the incidence is not high, clinicians should not overlook the most common crizotinibrelated adverse events. Furthermore, certain patients may continue to benefit from alectinib following longterm discontinuation of crizotinib therapy.
Related content
Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 10, Iss. 3, 2010-03 ,pp. :
Access to resources
Recommend
By Kaneda Hiroyasu Okamoto Isamu Sakai Kazuko Tanizaki Junko Takeda Masayuki Nishio Kazuto Nakagawa Kazuhiko
Acta Oncologica, Vol. 51, Iss. 7, 2012-09 ,pp. :
Crizotinib: an anaplastic lymphoma kinase inhibitor
By Gadgeel Shirish M Bepler Gerold
Future Oncology, Vol. 7, Iss. 8, 2011-08 ,pp. :